Oritavancin

證據等級: L5

預測適應症: 3 個

Oritavancin: From Gram-Positive Bacterial Infections to Bacteroidaceae Infectious Disease (Low-Confidence Prediction)

One-Sentence Summary

Oritavancin is a lipoglycopeptide antibiotic whose detailed mechanism-of-action record is currently missing from DrugBank, and it holds no market authorization in Taiwan. TxGNN’s top prediction suggests possible activity against Bacteroidaceae infectious disease, but this candidate — along with two other top-ranked predictions — is supported by zero clinical trials and zero publications, and the model’s own mechanistic rationale flags all three as pharmacologically implausible.

Quick Overview

Item	Content
Original Indication	Not available — no Taiwan license records; drug class (per mechanistic evidence) is a Gram-positive-targeting lipoglycopeptide antibiotic
Predicted New Indication	Bacteroidaceae infectious disease
TxGNN Prediction Score	99.48%
Evidence Level	L5 (model prediction only, no supporting studies)
US Market Status	✗ 未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for oritavancin is currently marked as a data gap in DrugBank. However, the TxGNN rationale text itself supplies mechanistic context: oritavancin is a lipoglycopeptide antibiotic that inhibits peptidoglycan (cell wall) synthesis in Gram-positive bacteria by binding the D-Ala-D-Ala terminus of the peptidoglycan precursor, while also disrupting bacterial membrane integrity.

None of the three top-ranked predictions in this evidence pack fit that mechanism:

Bacteroidaceae infectious disease — Bacteroides spp. are Gram-negative anaerobes. Their outer membrane physically blocks glycopeptide penetration, and oritavancin has no established clinical activity against Gram-negative organisms.
Ophthalmic herpes zoster — caused by Varicella-zoster virus, a viral pathogen. Oritavancin has no antiviral mechanism whatsoever; this pairing is categorically mismatched (antibacterial vs. antiviral).
Mycoplasma pneumoniae pneumonia — M. pneumoniae lacks a cell wall entirely, and is intrinsically resistant to all cell-wall-targeting agents, including glycopeptides.

In all three cases, the repurposing rationale supplied alongside the TxGNN score explicitly concludes that the high prediction score likely reflects knowledge-graph co-occurrence or embedding similarity rather than genuine pharmacological plausibility — i.e., these are probable false positives rather than credible repurposing leads.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Additional Predicted Indications (Ranks 2–3, Not Recommended)

Rank	Predicted Indication	TxGNN Score	Evidence Level	Mechanistic Assessment	Decision
2	Ophthalmic herpes zoster	99.03%	L5	Viral pathogen — no antibacterial mechanism applies	Hold
3	Mycoplasma pneumoniae pneumonia	99.01%	L5	Cell-wall-deficient organism — intrinsic resistance to glycopeptides	Hold

All three top TxGNN candidates (including rank 1 above) share the same evidence profile: no clinical trials, no literature, and a mechanistic rationale that argues against — rather than for — biological plausibility.

US Market Information

Oritavancin currently has no Taiwan market authorization (0 NDA/license records; market status: 未上市/Not Marketed). No product, dosage form, or approved-indication data is available for review.

Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and drug-drug interaction data are currently unavailable — TFDA label data is a blocking data gap [DG001] for this candidate.)

Conclusion and Next Steps

Decision: Hold

Rationale: All three predicted indications are at the earliest evaluation stage (S0/L5 — model prediction only, no clinical or literature support), and mechanistic review indicates each is likely a false positive: Gram-negative outer membrane exclusion (Bacteroidaceae), wrong drug class entirely (antiviral need vs. antibacterial drug — herpes zoster), and intrinsic target absence (cell-wall-deficient M. pneumoniae). Combined with the absence of any Taiwan market presence and missing core safety data, there is no basis to advance any of these candidates.

To proceed, the following is needed:

TFDA label warnings/contraindications (blocking gap — required before any S1 safety screening)
Confirmed mechanism of action and approved indication(s) for oritavancin via DrugBank/FDA labeling
If repurposing evaluation continues for this drug, redirect candidate screening toward Gram-positive pathogen indications consistent with its actual glycopeptide mechanism, rather than the three mechanistically incompatible candidates identified here
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.